Although most nuclear medical examinations using SPECT (single photon emission computed tomography) take place beyond hospitals, two to three times more SPECT exams than PET-CT exams are carried out within hospitals.
This technique is increasingly used to detect breast cancer and has been shown to improve diagnosis in many clinical situations. It is also allowing clinicians to detect previously unknown areas of breast cancer in women with newly diagnosed disease.
Currently there is a truly enormous hole in the ground in the city of Wiener Neustadt, Austria, but by summer 2012 MedAustron, one of the most modern centres for ion therapy and research in Europe, is to be built here.
Royal Philips Electronics is announcing 510(k) clearance from the Food and Drug Administration (FDA) for the company’s first commercially available whole body positron emission tomography/magnetic resonance (PET/MR) imaging system, the Ingenuity TF PET/MR.
It was not the sunshine of the Cote d’Azur in September that lured radiologists to picturesque Nice. Far more enticing was the stimulating programme offered by the Annual Scientific Meeting of Management in Radiology (MIR), which, for the first time, also included a Junior Radiologists Course.
In recent years, combined examination methods have increased, whereby two examination methods are used in a parallel examination, rather than performed separately. Frederik Giesel MD, Associate Professor of Radiology at the Nuclear Medicine Department, University of Heidelberg, and Philip Herold (Dipl. Econ.), Project Manager at RICT Heidelberg, report on the benefits.
2011 brought a second year for European and US scientists to meet up at the Annual Scientific Symposium on Ultra High Field Magnetic Resonance, held at the Max Delbrück Centre for Molecular Medicine Berlin-Buch (MDC), Germany, to present and discuss their recent findings. Along with technical improvements, the main issues of the one-day gathering were cardiac, cerebral and molecular MR imaging.…
A major public hospital has become the first in Paris to be equipped with a Gamma Knife, the device that enables the surgeon to operate on the brain with no blade or blood involved.
PredictAD is an EU-funded research project that develops objective and efficient methods for enabling earlier diagnosis of Alzheimer's disease. Diagnosis requires a holistic view of the patient combining information from several sources, such as, clinical tests, imaging and blood samples.
Every medical congress is an opportunity for the manufacturers to showcase their products. This year’s congress of the German Röntgen Society was no exception -- and one innovation particularly caught the attention of our European Hospital team: positron emission mammography, PEM for short.
CT-PET is the child of a forced marriage between nuclear medicine and radiology. A shared session at ECR 2011 in Vienna did little to assure there is a growing consensus between the two partners.
Although developments in molecular imaging still do not reach the high expectations placed upon them, the change in imaging is very obvious. Having been limited to the imaging of morphology, nowadays information on tissue characteristics, blood vessels or the metabolic behaviour of tumours provide many more insights, for example into response behaviour.
Thinking of the future of imaging, inevitably PET-MRI springs to mind. The fascination of this novel hybrid technology is great, seeing how it combines the best from three imaging areas: anatomy, function and metabolism. The further development of functional procedures in oncology is raising particularly high expectations. However, how extensive the use of this potentiated image information will…
Whole-body hybrid PET-MR scanners are emerging on the market and are expected to have a significant impact in diagnostic imaging particularly in oncology applications and also in other clinical domains, such as cardiology, inflammatory and infectious disease, as well as in neurological applications.
Molecular Imaging (MI) emerged in the early 21st Century as a discipline at the junction of molecular biology and in vivo imaging to enable the visualisation of the cellular function and the follow-up of the molecular processes in living organisms. Modalities available for MI encompass MRI, CT and ultrasound, PET, as well as Optical Imaging, and are by nature frequently experimental.
A leading radiologist is forecasting a ‘paradigm shift’ in breast imaging. Dr Peter Brader, from Department of Radiology, Division for Molecular and Gender Imaging, Medical University Vienna, envisages that diagnosis and treatment will move from a ‘one size fits all’ approach to one of personalised molecular medicine by 2025. He also foresees greater use of theranostics with combinations…
"One size fits all" – the phrase is a fact of life in terms of the drugs available to treat cancer patients today. This solution can bear tragic results. Only 25% of cancer patients currently respond to this ‘one size’ drugs administration. In addition, 100,000 patients die annually, in the USA alone, from the side effects of those drugs. Personalised therapies that are devised to suit…
When planning radiotherapy the combination of positron emission tomography (PET) and Computed tomography (CT) can provide a better outcome than CT alone. Michael Krassnitzer asked Terri Bresenham MSc BSc, Vice President for Molecular Imaging at GE Healthcare, for her views on the value of PET/CT, the new EANM guidelines, novel tracers and the future of other hybrid imaging technologies.
High resolution radionuclide imaging is a technique increasingly used to detect breast cancers and has already been shown to offer improved diagnosis in many clinical situations. The technique, which will be discussed at RSNA 2010 (28 November to 3 December, Chicago) , is also allowing clinicians to detect previously unknown areas of breast cancer in women with newly-diagnosed disease.
Late in 2009, GE Healthcare’s 64 slice PET/CT Discovery 690 began its use in the University Clinic for Nuclear Medicine in Innsbruck, Austria. Apart from routine clinical examinations for treatment control via FDG (fluorodeoxyglucose), the scanner is also employed in clinical research - particularly for Gallium 68DOTA PET/CT examination.
Molecular imaging, the discipline that unites molecular biology and in vivo imaging technologies to assess biological activity in the body, promises to open up ‘…an entire new universe,’ declared Dr Ralph Weissleder, of the Centre for Molecular Imaging Research at Massachusetts General Hospital, USA, in the journal Radiology. That was just one decade ago. And he was right. It has indeed…
2010 workshop in Aachen, Germany, in March, were welcomed by Professor Thomas M Deserno, head of the Medical Informatics Department at RWTH Aachen University and organiser of what turned out to be an ‘outstanding’ scientific programme.
In the current economic environment the introduction of novel imaging approaches and their reimbursement by payers is becoming increasingly difficult. Historically, this denotes a significant change, in that many currently accepted routine tests or interventions were accepted based on common sense, convincing experience or rapid adoption into clinical routine without much scrutiny.
Over the past decades new imaging technologies have substantially broadened the range of imaging applications in clinical medicine. For years anatomical imaging modalities, such as X-ray and CT, reveal high-resolution information of organs and tissues over extended imaging ranges. Lately, however, the idea of functional imaging e.g. the visualisation of physiology in vivo gains importance.
Molecular imaging, the discipline that unites molecular biology and in vivo imaging technologies to assess biological activity in the body, promises to open up ‘…an entire new universe,’ declared Dr Ralph Weissleder, of the Centre for Molecular Imaging Research at Massachusetts General Hospital, USA, in the journal Radiology. That was just one decade ago. And he was right. It has indeed…
